<DOC>
	<DOCNO>NCT01355133</DOCNO>
	<brief_summary>The purpose pilot clinical study determine intrasphincteric autologous myoblast injection combination electrical stimulation safe effective treat stress urinary incontinence , confirm optimal dose assess tolerability procedure .</brief_summary>
	<brief_title>Safety Efficacy Study Intrasphincteric Autologous Myoblast Injection Treat Stress Urinary Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>Female outpatient , predominant clinical diagnosis SUI Have discrete episodes incontinence ( , dry episode continuously leak urine , synchronous increase intraabdominal pressure coughing , sneeze , exercise , etc . ) Have positive Fixed Bladder Volume Cough Stress Test ( CST ) result ; post void residual volume &lt; 50 ml Report normal urinary diurnal ( ≤8/day ) nocturnal ( ≤2/night ) frequency per micturition history Have symptom SUI minimum 3 month prior study entry Can independently use toilet without difficulty If patient regularly use laxative , stool softener , stoolbulking agent ( example , fibre supplement ) , use product remain constant participation study . Competent comprehend , sign , date Ethics Committee approve informed consent form studyspecific procedure perform . Are woman nonchildbearing potential reason hysterectomy , surgery , natural menopause , woman childbearing potential test negative pregnancy time enrolment base urine pregnancy test agree use medically accept mean contraception ( example , intrauterine device [ IUD ] , oral injectable contraceptive , implant , barrier device , sterilization , abstinence , sex vasectomize male partner ) duration study . Women use oral contraceptive hormone replacement therapy must stable dose regimen great equal 3 month prior entry study . Previous diagnosis follow condition , disorder , disease urinary tract : Greater Stage I Anterior ( cystocoele ) , Apical ( uteri ) , Posterior ( rectocoele ) Compartment Prolepses per POPQ ) Ureteric bladder , urethral rectal fistula Uncorrected congenital abnormality lead urinary incontinence Interstitial cystitis Urinary urgency result leakage ( predominant symptom ) Adult enuresis Urodynamically prove : detrusor instability sensory urgency define first sensation bladder fill ( urge void ) &lt; 100 ml ; bladder capacity &lt; 300 ml void difficulty Have sensation time simple fill cystometry procedure Unstable systemic disease include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within 6 month enrollment Have symptomatic urinary tract infection ( UTI ) ; history four urinary tract infection precede year . Have prolong menstruation ( &gt; 14 day per month ) . Have history ( currently ) urogenital cancer . Suffer severe constipation define less one bowel movement per week Are pregnant , &lt; 12 month postpartum lactate Have major inpatient surgery within 3 month prior study entry Known infection human immunodeficiency virus ( HIV ) Known active infection Hepatitis B virus , Hepatitis C virus Lues . Any organic psychiatric disorder , opinion investigator , might prevent subject complete study interfere interpretation study result . Have antiincontinence prolapse surgery , include follow : Anterior Repair Needle Suspension Raz ; Pereyra ; Stamey ; Gittes ; Muzsnai procedures Retropubic Procedures : Marshall , Marchetti &amp; Krantz ; Burch procedures Sling Procedure Collagen Injections Artificial Sphincter . Use follow : Any antiincontinence device ( example , Reliance , Minigard , FemAssist ) include tampon use prevent incontinence participation study Vaginal pessary prolapse incontinence Any nonpharmacologic intervention incontinence prolapse ( example , electro stimulation , vaginal cone , device ) within 3 month prior study entry . Current use follow drug : antidepressant , duloxetine , monoamine oxidase inhibitor , clonidine , alphamethylDOPA , betablockers , guanethidine , reserpine , pentosan polysulfate , alphareceptor antagonists/agonists ( chronic use ) . Current use medication treatment urinary incontinence . Are medication regimen include estrogen , antiestrogens , diuretic dose and/or frequency stable least past 12 week , anticipated change course study . ≤ 30 day since receive investigational medicinal product device another clinical trial . Current enrollment another clinical trial permit . Allergy/ intolerance least one active ingredient excipients investigational product , e.g . bovine protein , gentamycin Have abuse disorder within 5 year prior study entry ; e.g . patient report regular consumption &gt; 21 alcoholic drink per week ( average 3 drink per day )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Urinary incontinence</keyword>
	<keyword>Myoblasts</keyword>
	<keyword>Muscle derive cell</keyword>
	<keyword>Stem cell</keyword>
</DOC>